A Tylenol recall is the latest shame for McNeil Consumer Healthcare, a subsidiary of Johnson and Johnson. Level of quality control practices at McNeil Consumer Healthcare are being investigated by Congress as the fifth Tylenol recall in 1 year gets under way. A pattern of consumer grievances describing a musty odor in the containers led to the current Tylenol recall. Article source - New Tylenol recall fifth in a year for Johnson and Johnson by Personal Money Store.
Tylenol 8-Hour recall
The latest Tylenol recall had been announced Monday. The McNeil Consumer Healthcare division of Johnson and Johnson's got involved on its own. About 128,000 bottles of 50-count Tylenol 8-hour Caplets were taken back by the company. The NY Times reports that McNeil initiated the Tylenol 8-Hour recall after consumers complained of a "musty or moldy odor" in goods sold within the United States of America and Puerto Rico. Before March, when the Fort Washington, Pa., plant had been closed, it made the batch of Tylenol that the business is now recalling. The musty smell probably originated from the very same thing that brought on the recall in January, June and July with goods that came from the McNeil factory in Puerto Rico and that had been a chemical that got to the Tylenol when the company had been treating wooden transport pallets.
Tylenol just keeps recalling
Several recalls this year by the Johnson and Johnson subsidiary prompted a Congressional inquiry. CNN accounts that last Nov, five lots of 100-count Tylenol Arthritis Pain were recalled for a stench causing nausea, stomach pain, vomiting and diarrhea. In December, the Tylenol recall was expanded to all lots of the product. The recall had been then expanded even further to non-prescription drugs causing smell and nausea with things for instance Tylenol and Motrin. Level of quality control and safety concerns brought on 50 children's medicines to be within the recall in May.
Making sure you manage facilities better
Johnson and Johnson closed the McNeil plant in April. Reuters reports the company has since been revamping the plant's quality control plans to address violations uncovered in an investigation by inspectors from the U.S. FDA. Based on the FDA, the factory had contaminated drug ingredients. There was also dust and grime everywhere. Drugs manufactured at the Fort Washington plant contributed sales of about $650 million a year to Johnson and Johnson's bottom line. Bloomberg reports that the recalls and facility closings will reduce the company's sales this year by about $600 billion.
New York Times